Moderna, Inc. Files SEC Form 4 Document for August 5, 2022

A U.S. Securities and Exchange Commission filing by Moderna, Inc. has been posted, detailing the company's information as of August 5, 2022. The filing, processed by the SEC, discloses financial transactions and ownership details of the company. Moderna, Inc. is a publicly-traded biotechnology company focused on developing mRNA-based vaccines and therapeutics. As a result of this filing, investors and stakeholders have gained insight into the company's financial dealings and corporate structure.

Key Takeaways:

• The SEC filing was made by Moderna, Inc. on August 5, 2022, as per the company's regulatory obligations.
• The filing was made to disclose changes in the company's ownership and financial transactions, as required by the Securities Exchange Act of 1934.
• The document, filed as Form 4, contains details on the reporting person's relationship to the company and purchases and sales of equity securities.
• The SEC filing is a mandatory document that must be submitted by publicly-traded companies, such as Moderna, Inc., for transparency and regulatory compliance.
• The SIC code for Moderna, Inc. is 2836, corresponding to the Biological Products industry category.
• The company's contact information, as listed in the filing, is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139, with a phone number of 617-714-6500.
• The SEC filing is publicly available on the SEC website, accessible through the link https://www.sec.gov/Archives/edgar/data/1682852/0001127602-22-020582-index.html.

Statistics:

• Date of SEC filing: August 5, 2022
• SEC filing number: 0001127602-22-020582
• SIC code for Moderna, Inc.: 2836
• Industry category: Biological Products
• Phone number: 617-714-6500
• Address: 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139

Sources:

• SEC Filing (Form 4) by Moderna, Inc. (August 5, 2022)
• U.S. Securities and Exchange Commission (SEC) website
• NewsRx LLC (publication date not specified)